Hu Xingwei, Liu Wenhan, Liu Jianhua, Wang Bojian, Qin Xiaosong
Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Liaoning Clinical Research Center for Laboratory Medicine, Shenyang, Liaoning, China.
Front Med (Lausanne). 2024 Jun 19;11:1372434. doi: 10.3389/fmed.2024.1372434. eCollection 2024.
While liver fibrosis remains a serious, progressive, chronic liver disease, and factors causing damage persist, liver fibrosis may develop into cirrhosis and liver cancer. However, short-term liver fibrosis is reversible. Therefore, an early diagnosis of liver fibrosis in the reversible transition phase is important for effective treatment of liver diseases. Chitinase-3-like protein 1 (CHI3L1), an inflammatory response factor that participates in various biological processes and is abundant in liver tissue, holds promise as a potential biomarker for liver diseases. Here, we aimed to review research developments regarding serum CHI3L1 in relation to the pathophysiology and diagnosis of liver fibrosis of various etiologies, providing a reference for the diagnosis, treatment, and prognosis of liver diseases.
尽管肝纤维化仍是一种严重的、进行性的慢性肝病，且导致损伤的因素持续存在，肝纤维化可能发展为肝硬化和肝癌。然而，短期肝纤维化是可逆的。因此，在可逆转变阶段早期诊断肝纤维化对于有效治疗肝病很重要。几丁质酶-3样蛋白1（CHI3L1）是一种参与多种生物过程且在肝组织中含量丰富的炎症反应因子，有望成为肝病的潜在生物标志物。在此，我们旨在综述血清CHI3L1与各种病因肝纤维化的病理生理学及诊断相关的研究进展，为肝病的诊断、治疗和预后提供参考。
